Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
1 other identifier
observational
33
1 country
2
Brief Summary
The primary aim is to describe platelet function in adult patients treated with extracorporeal membrane oxygenation (ECMO). A clarification of the platelet function in these critically ill patients contributes to an understanding of the mechanisms underlying their coagulopathy. The present study is a substudy to the study entitled; "Coagulopathy During Extracorporeal Membrane Oxygenation" (pending Clinical Trial ID number).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2017
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
November 22, 2017
CompletedFirst Posted
Study publicly available on registry
November 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2019
CompletedMay 26, 2022
May 1, 2022
2.1 years
November 22, 2017
May 25, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in platelet function
Platelet function on day 3 compared with day 1 on ECMO. Measured by flow cytometry
Platelet function measured day 1 and day 3 on ECMO
Secondary Outcomes (3)
Changes in platelet aggregation
Platelet function measured every morning from day 1 to day 8 on ECMO (except weekends).
Immature platelet count
Measured every morning from day 1 to day 8 on ECMO (except weekends)
Platelet count
Measured every morning from day 1 to day 8 on ECMO (except weekends)
Eligibility Criteria
Patients treated with ECMO at the Intensive Care Unit East, Aarhus University Hospital.
You may qualify if:
- Treatment with veno-venous or veno-arterial ECMO
- Age ≥18 years
You may not qualify if:
- ECMO treatment initiated post-operatively
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aarhus University Hospitallead
- University of Aarhuscollaborator
Study Sites (2)
Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital
Aarhus, 8000, Denmark
Department of Anaesthesiology and Intensive Care Unit East, Aarhus University Hospital
Aarhus, 8000, Denmark
Study Officials
- PRINCIPAL INVESTIGATOR
Camilla Mains Balle, Research fellow
Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital
- STUDY CHAIR
Anne-Mette Hvas, Professor, MD, PhD
Centre of Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital
- STUDY CHAIR
Anni Nørgaard Jeppesen, MD, PhD
Department of Anaesthesiology and Intensive Care Unit East, Aarhus University Hospital
- STUDY CHAIR
Steffen Christensen, MD, PhD
Department of Anaesthesiology and Intensive Care Unit East, Aarhus University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2017
First Posted
November 28, 2017
Study Start
September 1, 2017
Primary Completion
September 30, 2019
Study Completion
November 30, 2019
Last Updated
May 26, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share